Nutex Health furnishes anticipated results update

Nutex Health Inc. filed a current report announcing that on August 14, 2025 it issued a press release with certain anticipated financial results and related information.

Rhea-AI Filing Summary

Nutex Health Inc. filed a current report announcing that on August 14, 2025 it issued a press release with certain anticipated financial results and related information. The company furnished this press release as Exhibit 99.1, specifying that the information in Item 2.02 and the exhibit is being provided for informational purposes and is not deemed filed under the Exchange Act, nor automatically incorporated into other securities filings unless specifically referenced.

8-K Event Classification

Item 2.02 — Results of Operations and Financial Condition

1 item

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Nutex Health (NUTX) disclose in this 8-K filing?

Nutex Health disclosed that it issued a press release on August 14, 2025 containing certain anticipated financial results and other information, which is furnished as Exhibit 99.1.

Which Item of Form 8-K did Nutex Health (NUTX) use for this disclosure?

Nutex Health used Item 2.02, Results of Operations and Financial Condition, to furnish its press release with anticipated financial results.

Is the Nutex Health (NUTX) press release in this 8-K considered filed with the SEC?

The company states that the information in Item 2.02 and Exhibit 99.1 is furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities.

Can the Nutex Health (NUTX) press release be incorporated into other SEC filings?

The press release and Item 2.02 information will only be incorporated into other SEC filings if Nutex Health expressly does so by specific reference.

What exhibits are included with this Nutex Health (NUTX) 8-K?

The filing includes Exhibit 99.1, a press release dated August 14, 2025, and Exhibit 104, the cover page interactive data file embedded within the Inline XBRL document.

Who signed the Nutex Health (NUTX) 8-K report?

The report was signed on behalf of Nutex Health Inc. by Jon C. Bates, Chief Financial Officer, dated August 14, 2025.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 08/14/2025 - 04:56 PM EDT Learn about SEC filing dates

0001479681FALSE00014796812025-08-142025-08-14

UNITED STATES 

SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549 

FORM 8-K 

CURRENT REPORT 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 

Date of Report (Date of earliest event reported): August 14, 2025 

NUTEX HEALTH INC.  

(Exact name of registrant as specified in its charter) 

Delaware			001-41346			11-3363609
(State or Other Jurisdiction  of Incorporation)			(Commission File Number)			(I.R.S. Employer  Identification No.)

  

6030 S. Rice Ave, Suite C, Houston, Texas 77081 

(Address of principal executive offices) (zip code) 

(713) 660-0557 

(Registrant’s telephone number, including area code) 

N/A 

(Former name or former address, if changed since last report) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: 

☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communication pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communication pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) 

Securities registered pursuant to Section 12(b) of the Act: 

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, $0.001 par value

NUTX

The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2). 

Emerging growth company ☐ 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2025, we issued a press release containing certain anticipated financial results and other information. The press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information furnished in this Item 2.02 and Exhibit 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits

Exhibit No.			Description of Exhibit
99.1			Press Release dated August 14, 2025
104			Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Date: August 14, 2025			NUTEX HEALTH INC.
			By:			/s/ Jon C. Bates
						Jon C. Bates  Chief Financial Officer